Phase 1b/2 trial expected to initiate 1Q 2019

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Phase 1b/2 trial expected to initiate 1Q 2019

posted on Jan 04, 2019 10:51AM

Looking forward to hearing more details at Biotech Showcase about the Zenith/Pfizer collaborative trial in triple negative breast cancer that was previously announced to initiate Q1 2019. Nothing on ClincialTrials.gov yet. Also, looking forward to update on the metastatic castrate resistant prostate cancer program, since the data shared at the Sept AGM and Nov Bio-Europe was only updated through 8/22/18 and 9/19/18, respectively.